- This event has passed.
The Liver Meeting® 2016
The American Association for the Study of Liver Diseases (AASLD) will see you in Boston, MA, where more than 9,500 hepatologists and hepatology health professionals from across the nation and around the world will gather at The Liver Meeting® to exchange the latest liver diseases research, discuss treatment outcomes, and interact with colleagues at the annual must-attend even in the science and practice of hepatology.
CHLPI’s Robert Greenwald will present on the “Medicaid and Access to Hepatitis C Medications: A Panel Discussion” panel.
In spite of the availability of highly effective DAA therapy for HCV, including those with advanced disease, restrictions on access by many state Medicaid providers has kept these lifesaving treatments out of reach to many patients. CMS has encouraged state Medicaid providers to increase access to HCV therapy, but non-medical restrictions remain in place in many states. Advocacy groups have lobbied state Medicaid providers to little effect. The criteria for access provided by the AASLD/IDSA HCV Guidance document have also had little impact.
As the major governing body for hepatology, the AASLD has an important role in providing guidance and education to its members regarding this important issue. Therefore, a one hour panel session will be convened at The Liver Meeting® to bring together different stakeholders to discuss and debate this issue.